Darwin AG (7V0) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Darwin AG stock €1.79, price €6.35, that is 71.8% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
39‑month range €5.64 – €11.88 · fair‑value band €1.26 – €2.34 · the €6.35 price screens above the €1.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Darwin in your weekly email
Every Wednesday you see whether Darwin is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Darwin AG operates in the healthcare industry. The company offers dietary supplements and cosmetics products. It also provides consulting and support services. The company was incorporated in 2021 and is based in Munich, Germany.
Stock analysis
Darwin AG (7V0) currently trades at €6.35, while our model-based Fair Value estimate is €1.79, 72% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of €4.88 per share, and 1 of the 11 models we run sit above the €6.35 price.
Bear case: the Multiples group reads lowest at €1.00, and 10 of the 11 models stay below the price. Data coverage for this calculation is low.
Scenario range: €1.26 (bear) to €2.34 (bull), the price of €6.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Darwin AG reported revenue of €54.3M in FY2025 versus €111M in FY2021, a compound −16.4%/yr. Reported net income was €545K in FY2025, compounding −59.0%/yr from FY2021.
Key figures
Market cap €76.2M Micro · P/E ratio 127.0 · P/S ratio 1.28 · EPS (TTM) €0.0500 · Dividend yield 4.5% · Net margin 1.0% · Return on equity 0.5% · Return on assets (EBIT) 10.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, 7V0 screens richer than that median.
Fair Value models
Bear€1.26Fair Value €1.79Bull€2.34
Price €6.35 · Downside -71.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0429 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income€4.57€4.88€5.3271
Gordon GGM€2.32€4.18€5.7563
DDM Multi-Stage€2.32€3.81€4.4663
All 11 models by family
Earnings-Based
Graham-Dodd€0.3100€2.16€3.0359
Lynch FV€1.11€1.59€2.0757
PEG = 1.0€1.11€1.59€2.0753
Dividend Discount
Gordon GGM€2.32€4.18€5.7563
DDM Multi-Stage€2.32€3.81€4.4663
Multiples
P/E Multiple€0.7500€1.00€1.2563
P/S Multiple€0.5800€0.7700€0.970058
P/B Multiple€26.13€34.84€43.5455
Asset-Based
NCAV (Graham)€3.11€4.72€5.9054
Economic Profit
Residual Income€4.57€4.88€5.3271
Growth Earnings
Growth-Adj P/E€1.48€2.11€2.7563
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+114.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.3%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−58.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−62.9%
Dividend (yield on the price)4.5%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → −20%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−71.8% · Below median
Profitability
Return on equity (12 months)0.5% · Above median
Return on assets0.5% · Above median
Net margin (12 months)−6.6% · Below median
Operating margin (12 months)−18.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−7.1% · Below median
Dividend yield (12 months)4.5% · Top 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)127.0× · Priciest 25%
P/B0.76× · Cheapest 25%
P/S (12 months)1.46× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)2· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)90· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Darwin AG Fair Value". https://www.fairvalue-calculator.com/stock/7V0
Frequently asked questions
Is Darwin AG (7V0) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €1.79 versus a price of €6.35, about 72% lower (overvalued).
What is the fair value of 7V0?
Our model-based fair value for Darwin AG is €1.79 (as of Nov 6, 2026), built from audited fundamentals. The current price: €6.35.
What is the quality score of 7V0?
Darwin AG has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Darwin AG (7V0)?
Our model-based price target is the fair value of €1.79 (as of Nov 6, 2026) from 11 valuation models. Cautious scenario €1.26, optimistic scenario €2.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Darwin AG stock forecast for 2026?
Our models put fair value at €1.79, about 72% lower versus a price of €6.35 (overvalued). Cautious scenario €1.26, optimistic scenario €2.34. The calculation is refreshed regularly with new filings.
What is the revenue of Darwin AG (7V0)?
Darwin AG reported trailing-twelve-month revenue of about €52.3M (latest available figure, as of Nov 6, 2026).
Does Darwin AG pay a dividend?
Darwin AG currently shows a dividend yield of 4.52% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Darwin AG (7V0)?
Darwin AG has a dividend yield of 4.5%.
What is the intrinsic value of Darwin AG (7V0)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Darwin AG it is €1.79 per share (as of Nov 6, 2026), against a price of €6.35. It is the blended result of 11 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Darwin AG stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 7V0 trades above its calculated fair value: price €6.35, fair value €1.79, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7V0?
No. The price is what the market pays today (€6.35); the fair value is what the company's own numbers justify (€1.79). For Darwin AG the two are €4.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is Darwin AG worth?
The market values Darwin AG at about €76.2M (market capitalisation, as of Nov 6, 2026). Per share that is €6.35; our models calculate a fair value of €1.79 per share.
What do the bullish and bearish scenarios say about 7V0?
Our models span a range for Darwin AG: cautious scenario €1.26, base €1.79, optimistic €2.34 per share (as of Nov 6, 2026, price €6.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7V0?
Darwin AG trades at a price-to-earnings ratio of 127.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €1.79 is built from several models across several years. Other multiples: P/B 0.8, P/S 1.5.
How solid is the balance sheet of Darwin AG (7V0)?
Balance-sheet figures for Darwin AG (as of Nov 6, 2026): return on equity 0.5%, debt of 0.02 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 7V0 from its 52-week high?
Darwin AG trades at €6.35, about 41% below its 52-week high of €10.83 and 12% above the low of €5.64 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.79 is for.
Which stocks are comparable to Darwin AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Darwin AG stock attractive at the current price?
The data as of Nov 6, 2026: price €6.35, calculated fair value €1.79 (−72%), Quality Score 40/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7V0 calculated?
We run Darwin AG through 11 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €1.79 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Darwin AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Darwin AG (7V0)?
The closing price on Nov 6, 2026 was €6.35. Our model-based fair value is €1.79, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Darwin AG right now?
The price sits above even our optimistic bull case (€2.34). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€1.26 to €2.34) leaves room in how you read the outcome.
Key figures of Darwin AG
How large is the market capitalisation of Darwin AG (7V0)?
The market capitalisation of Darwin AG is €76.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Darwin AG (7V0)?
The price-to-sales ratio of Darwin AG is 1.28 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Darwin AG (7V0)?
Earnings per share at Darwin AG are €0.0500 (price ÷ EPS = P/E 127.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Darwin AG (7V0)?
The dividend yield of Darwin AG is 4.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Darwin AG (7V0)?
The net margin of Darwin AG is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Darwin AG (7V0)?
The return on equity (ROE) of Darwin AG is 0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Darwin AG (7V0)?
On an EBIT basis the return on assets of Darwin AG is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Darwin AG (7V0)?
The operating margin of Darwin AG is −18.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Darwin AG (7V0)?
Revenue at Darwin AG is growing −7.1% versus a year earlier (3y avg −36.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Darwin AG (7V0) generate?
The free cash flow of Darwin AG is −€21.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Darwin AG in the live analysis
One click puts Darwin AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026